Qiagen NV
QGEN48.290USD
-0.160-0.33%
Handelsschluss 01/09, 16:00（ET）Kurse um 15 Minuten verzögert
10.45BMarktkapitalisierung
25.83KGV TTM
mehr Informationen über Qiagen NV Unternehmen
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Qiagen NV Informationen
BörsenkürzelQGEN
Name des UnternehmensQiagen NV
IPO-datumSep 01, 1996
CEOBernard (Thierry)
Anzahl der mitarbeiter5765
WertpapierartOrdinary Share
GeschäftsjahresendeSep 01
AddresseHulsterweg 82
StadtVENLO
BörseNASDAQ OMX NASDAQ Basic NYSE
LandNetherlands
Postleitzahl5912 PL
Telefon31773556600
Websitehttps://www.qiagen.com/
BörsenkürzelQGEN
IPO-datumSep 01, 1996
CEOBernard (Thierry)
Führungskräfte von Qiagen NV
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Roland Sackers
Mr. Roland Sackers
Managing Director, Chief Financial Officer, Member of the Executive Board
Managing Director, Chief Financial Officer, Member of the Executive Board
383.09K
+143556.00%
Mr. Thierry Bernard
Mr. Thierry Bernard
Chief Executive Officer, Managing Director, Member of the Executive Board
Chief Executive Officer, Managing Director, Member of the Executive Board
312.13K
+134537.00%
Dr. Metin Colpan, Ph.D.
Dr. Metin Colpan, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
171.79K
-227680.00%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
47.22K
+4436.00%
Prof. Dr. Ross L. Levine, M.D.
Prof. Dr. Ross L. Levine, M.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
16.27K
+3835.00%
Prof. Dr. Elaine R. Mardis, Ph.D.
Prof. Dr. Elaine R. Mardis, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
3.97K
+3973.00%
Mr. Stephen H. (Steve) Rusckowski
Mr. Stephen H. (Steve) Rusckowski
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
24.00
--
Dr. Toralf Haag, Ph.D.
Dr. Toralf Haag, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Eva Pisa, Ph.D.
Dr. Eva Pisa, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mr. Bert van Meurs
Mr. Bert van Meurs
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Roland Sackers
Mr. Roland Sackers
Managing Director, Chief Financial Officer, Member of the Executive Board
Managing Director, Chief Financial Officer, Member of the Executive Board
383.09K
+143556.00%
Mr. Thierry Bernard
Mr. Thierry Bernard
Chief Executive Officer, Managing Director, Member of the Executive Board
Chief Executive Officer, Managing Director, Member of the Executive Board
312.13K
+134537.00%
Dr. Metin Colpan, Ph.D.
Dr. Metin Colpan, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
171.79K
-227680.00%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
47.22K
+4436.00%
Prof. Dr. Ross L. Levine, M.D.
Prof. Dr. Ross L. Levine, M.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
16.27K
+3835.00%
Prof. Dr. Elaine R. Mardis, Ph.D.
Prof. Dr. Elaine R. Mardis, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
3.97K
+3973.00%
Umsatzaufteilung
Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Consumables and Related Revenues
481.20M
90.35%
Instrumentation
51.38M
9.65%
Nach RegionUSD
Name
Umsatz
Anteil
United States
286.67M
53.83%
Europe & Middle East & Africa
172.58M
32.40%
Asia, Pacific & Rest of the World
73.33M
13.77%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Consumables and Related Revenues
481.20M
90.35%
Instrumentation
51.38M
9.65%
Aktionärsstatistik
Aktualisiert: Mon, Nov 17
Aktualisiert: Mon, Nov 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Wellington Management Company, LLP
10.76%
MFS Investment Management
10.56%
The Vanguard Group, Inc.
4.30%
T. Rowe Price International Ltd
3.47%
DWS Investment GmbH
2.13%
Andere
68.78%
Aktionäre
Aktionäre
Anteil
Wellington Management Company, LLP
10.76%
MFS Investment Management
10.56%
The Vanguard Group, Inc.
4.30%
T. Rowe Price International Ltd
3.47%
DWS Investment GmbH
2.13%
Andere
68.78%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
48.66%
Investment Advisor
26.06%
Research Firm
5.08%
Pension Fund
1.63%
Sovereign Wealth Fund
1.60%
Hedge Fund
1.10%
Bank and Trust
1.09%
Individual Investor
0.44%
Insurance Company
0.07%
Andere
14.27%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
988
176.43M
85.64%
-25.04M
2025Q3
996
177.81M
82.00%
-32.33M
2025Q2
996
189.55M
87.53%
+6.64M
2025Q1
1017
179.03M
82.67%
+27.58M
2024Q4
1010
129.03M
59.70%
-70.06M
2024Q3
1010
183.22M
84.72%
-23.62M
2024Q2
1002
184.34M
84.75%
+8.40M
2024Q1
988
165.20M
76.61%
-7.18M
2023Q4
993
165.11M
76.72%
-10.52M
2023Q3
987
159.93M
74.32%
-12.21M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Wellington Management Company, LLP
23.33M
10.76%
-2.69M
-10.35%
Sep 30, 2025
MFS Investment Management
22.91M
10.56%
-570.88K
-2.43%
Sep 30, 2025
The Vanguard Group, Inc.
9.33M
4.3%
+169.45K
+1.85%
Sep 30, 2025
T. Rowe Price International Ltd
7.52M
3.47%
+1.59M
+26.73%
Sep 30, 2025
DWS Investment GmbH
4.62M
2.13%
+1.32M
+39.94%
Sep 30, 2025
EARNEST Partners, LLC
4.21M
1.94%
+6.14K
+0.15%
Sep 30, 2025
Amundi Asset Management, SAS
4.15M
1.91%
+170.89K
+4.30%
Sep 30, 2025
Boston Partners
4.02M
1.85%
+594.42K
+17.37%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.98M
1.84%
-16.38M
-80.43%
Sep 30, 2025
BofA Global Research (US)
3.61M
1.66%
+2.63M
+269.19%
Oct 21, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
First Trust Nasdaq Lux Digi Health Solutions ETF
4.04%
Global X Genomics & Biotechnology ETF
3.81%
Invesco Biotechnology & Genome ETF
2.54%
VanEck Biotech ETF
1.79%
ROBO Global Healthcare Technology & Innovation ETF
1.51%
Pacer US Large Cap Cash Cows Growth Leaders ETF
1.26%
iShares Health Innovation Active ETF
1.21%
First Trust Health Care Alphadex Fund
0.91%
Franklin Genomic Advancements ETF
0.86%
WisdomTree International Multifactor Fund
0.72%
Mehr Anzeigen
First Trust Nasdaq Lux Digi Health Solutions ETF
Anteil4.04%
Global X Genomics & Biotechnology ETF
Anteil3.81%
Invesco Biotechnology & Genome ETF
Anteil2.54%
VanEck Biotech ETF
Anteil1.79%
ROBO Global Healthcare Technology & Innovation ETF
Anteil1.51%
Pacer US Large Cap Cash Cows Growth Leaders ETF
Anteil1.26%
iShares Health Innovation Active ETF
Anteil1.21%
First Trust Health Care Alphadex Fund
Anteil0.91%
Franklin Genomic Advancements ETF
Anteil0.86%
WisdomTree International Multifactor Fund
Anteil0.72%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
May 07, 2025
QGEN.NB Final Cash Dividend of gross USD 0.25 paid on Jul 10, 2025 going ex on Jul 02, 2025
Jul 02, 2025
Jul 10, 2025
Jul 02, 2025
Aktien-Split
Datum
Art
Verhältnis
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 18, 2024
Merger
25→24.25
Jan 18, 2024
Merger
25→24.25
Datum
Art
Verhältnis
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 18, 2024
Merger
25→24.25
Jan 18, 2024
Merger
25→24.25
Jan 18, 2024
Merger
25→24.25
Jan 18, 2024
Merger
25→24.25
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Qiagen NV?
Die fünf größten Anteilseigner von Qiagen NV sind:
Wellington Management Company, LLP hält 23.33M Aktien, was 10.76% der Gesamtaktien entspricht.
MFS Investment Management hält 22.91M Aktien, was 10.56% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 9.33M Aktien, was 4.30% der Gesamtaktien entspricht.
T. Rowe Price International Ltd hält 7.52M Aktien, was 3.47% der Gesamtaktien entspricht.
DWS Investment GmbH hält 4.62M Aktien, was 2.13% der Gesamtaktien entspricht.
Wellington Management Company, LLP hält 23.33M Aktien, was 10.76% der Gesamtaktien entspricht.
MFS Investment Management hält 22.91M Aktien, was 10.56% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 9.33M Aktien, was 4.30% der Gesamtaktien entspricht.
T. Rowe Price International Ltd hält 7.52M Aktien, was 3.47% der Gesamtaktien entspricht.
DWS Investment GmbH hält 4.62M Aktien, was 2.13% der Gesamtaktien entspricht.
Was sind die drei wichtigsten Anteilseigner-Typen von Qiagen NV?
Die drei wichtigsten Anteilseigner-Typen von Qiagen NV sind:
Wellington Management Company, LLP
MFS Investment Management
The Vanguard Group, Inc.
Wellington Management Company, LLP
MFS Investment Management
The Vanguard Group, Inc.
Wie viele Institutionen halten Anteile an Qiagen NV (QGEN)?
Mit Stand vom 2025Q4 halten 988 Institutionen Anteile an Qiagen NV, mit einem Gesamtmarktwert von etwa 176.43M, was 85.64% der Gesamtanteile entspricht. Im Vergleich zum 2025Q3 ist der institutionelle Aktienbesitz um 3.64% gestiegen.
Was ist die größte Einnahmequelle von Qiagen NV?
Am FY2025Q3 erzielte das Geschäft mit Consumables and Related Revenues für Qiagen NV den höchsten Umsatz in Höhe von 481.20M, was 90.35% des Gesamtumsatzes entspricht.
